updated analysis of the observational GioTag study
Maximilian J Hochmair (Author), Alessandro Morabito (Author), Desiree Hao (Author), Cheng-Ta Yang (Author), Ross A Soo (Author), James C-H Yang (Author), Rasim Gucalp (Author), Balazs Halmos (Author), Lara Wang (Author), Angela Märten (Author), Tanja Čufer (Author)

Abstract

Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors.

Keywords

osimertinib;raziskava GioTag;GioTag study;

Data

Language: English
Year of publishing:
Typology: 1.01 - Original Scientific Article
Publisher: Future Medicine Ltd
UDC: 616.2
COBISS: 2048610929 Link will open in a new window
ISSN: 1744-8301
Views: 917
Downloads: 559
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary keywords: Carcinoma, non-small cell lung;Therapy;Drug therapy;Afatinib;Nedrobnocelični karcinom pljuč;Terapija;Terapija z zdravili;
Source comment: Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Tanja Cufer; Opis vira z dne 10. 1. 2020;
Pages: str. 2905-2914
Volume: ǂVol. ǂ15
Issue: ǂiss. ǂ25
Chronology: Sep. 2019
DOI: 10.2217/fon-2019-0346
ID: 12014831